NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one n...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in ...
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to ...
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five ...
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.